FDA OKs higher dose insulin glargine for kids, plus more top stories in endocrinology
Click Here to Manage Email Alerts
The top stories in endocrinology last week included the FDA’s approval of a higher dose insulin glargine for children with diabetes, along with new data that suggest the readmission rate after pituitary surgery in the United States has remained unchanged since 2010.
Find all of last week’s top stories in endocrinology news here.
FDA approves higher-dose insulin glargine for children with diabetes
The FDA recently approved an expanded indication for insulin glargine injection 300 U/mL to improve glucose response in children aged 6 years and older with diabetes, according to a press release from Sanofi. Read more.
National readmission rate remains at 10% after pituitary surgery
The national 30-day unplanned readmission rate following transsphenoidal surgery for pituitary lesion held at 10.4% between 2010 and 2015, despite a national focus on reducing readmission rates, according to findings from a database analysis published in Pituitary. Read more.
FDA draft guidance aims to facilitate biosimilar insulin development
The FDA recently announced new draft guidance designed to help facilitate the development of insulin products for people with type 1 and type 2 diabetes, part of a broader effort to increase market competition, lower costs for patients and payors and increase access and product choice. Read more.
Work together to achieve wellness goals of people living with diabetes
Susan Weiner, MS, RDN, CDE, CDN, FAADE, recently talked with clinical psychologist and diabetes educator Nicole M. Bereolos, PhD, MPH, MSCP, CDE, about how health care providers can better engage people with diabetes to help them devise and reach goals for living well with their condition. Read more.
Endothelial function metric may predict CV events among asymptomatic adults with type 2 diabetes
Adults with type 2 diabetes who went on to experience a major adverse cardiovascular event had decreased flow-mediated dilation, which may indicate worse endothelial function, according to findings published in Diabetes/Metabolism Research and Reviews. Read more.